SCHEMBL5221412

SCHEMBL5221412

Clc1ccc(-n2cc(-c3nc4ccccc4o3)cn2)c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
RAB9A P51151 4/20 0.41
NPC1 O15118 4/20 0.41
ATM Q13315 1/20 0.41
PTPN2 P17706 3/20 0.39
PTPN1 P18031 3/20 0.39
PTPN5 P54829 3/20 0.39
HSPD1 P10809 2/20 0.39
HSPE1 P61604 2/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PTGS2 P35354 1/20 0.39
HCRTR1 O43613 1/20 0.39
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217497 0.83 SMN1; SMN2 (0.48) ALDH1A1HSD17B10MEN1KMT2ARAB9A
SCHEMBL5219184 0.77 RAB9A (0.44) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5217836 0.77 ALDH1A1 (0.50) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL6174671 0.77 ALDH1A1 (0.50) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL99579 0.77 PRKCI (0.53) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5218794 0.76 NPC1 (0.48) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5221469 0.76 NPC1 (0.47) MAPTALDH1A1RAB9ANPC1KDM4E
SCHEMBL5217080 0.75 NPC1 (0.45) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL5215874 0.74 NPC1 (0.46) MAPTALDH1A1HSD17B10MEN1KMT2A
SCHEMBL30954649 0.74 NPC1 (0.56) MAPTALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C MAPT 2547/4885ALDH1A1 2988/4885HSD17B10 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.